Trial Profile
MITO END-3: A Randomized Phase II Trial of Carboplatin+Paclitaxel Compared to Carboplatin+Paclitaxel+Avelumab in Advanced (Stage III-IV) or Recurrent Endometrial Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 29 Dec 2023
Price :
$35
*
At a glance
- Drugs Avelumab (Primary) ; Carboplatin; Paclitaxel
- Indications Carcinoma; Endometrial cancer
- Focus Therapeutic Use
- Acronyms MITO-END3
- 09 Nov 2023 Planned primary completion date changed from 1 Apr 2023 to 1 Dec 2023.
- 23 Mar 2023 Planned primary completion date changed from 1 Feb 2023 to 1 Apr 2023.
- 01 Mar 2023 Primary endpoint has been met (progression free survival), as per Results published in the Lancet Oncology